Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement
Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.
Immunosuppressants Reduce Venous Thrombosis Relapses in Behets Disease.
Desbois1, anne Claire, Wechsler2, Bertrand, Piette3, Jean-Charles, Boutin1, Du, Amoura4, Zahir, Koskas1, Fabien, Cacoub4, Patrice
Department of Internal Medicine and 2 Laboratory I3 Immunology, Immunopathology, Immunotherapy, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris
Hopital de la Pitie, Paris, France
CHU Pitié-Salpêtrière, Paris, France
Department of Internal Medicine and Laboratory I3 "Immunology, Immunopathology, Immunotherapy", UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris
Venous disease is more common than arterial involvement and its prevalence may account 14% to 39% of patients with Behçet's disease (BD) according to studies. Venous thrombosis in BD is a severe disorder which may affect many differents sites including inferior vena cava, superior vena cava, pulmonary artery, supra-hepatic vessels and cardiac cavities. Treatment and outcome of venous thrombosis in BD is not well defined.
Among a cohort of 820 BD patients, 296 patients (36.7%) [73.6% of male and the median (Q1-Q3) age was 30 (2436) years] fulfilling the international criteria of BD and with venous thrombosis were reported. Factors associated with relapses of thrombosis and mortality were assessed.
There was a total of 582 venous thrombosis events including 555 deep and 27 superficial thrombosis. Main deep thrombosis localizations included limbs (n=323, 55.1%), cerebral veins (n=77, 13.1%), pulmonary embolism (n=57, 9.7%), vena cava (n=63, 10.7%), Budd Chiari syndrome (n=14, 2.4%) and cervical veins (n=13, 2.2%). The mortality rate was 6.4% (19/296) after a median (Q1-Q3) follow up of 4.75  years. In univariate analysis, death was associated with male gender (p=0.0088), cardiac involvement (p=0.026) and Budd Chiari syndrome (p=0.004). In multivariate analysis, factors that prevent relapses of venous thrombosis were immunosuppressants [HR 0.27 (0.140.52), p<0.001] and corticosteroids [HR 0.62 (0.400.97), p= 0.058].
Budd Chiari syndrome is the more severe venous involvement in our series of BD. Immunosuppressants use reduce the relapses of venous thrombosis in BD.
To cite this abstract, please use the following information:
Desbois, anne Claire, Wechsler, Bertrand, Piette, Jean-Charles, Boutin, Du, Amoura, Zahir, Koskas, Fabien, et al; Immunosuppressants Reduce Venous Thrombosis Relapses in Behets Disease. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :2395